CRL

AI Research

European discovery and CDMO assets sold; stock down 9.6% on restructuring and mixed 2026 outlook

Charles River Laboratories announced definitive agreements to sell certain European Discovery Services assets and its CDMO and Cell Solutions businesses, with the divestitures expected to cut 2026 revenue but lift margins and non-GAAP EPS. The stock fell 9.6% on March 12, 2026, as investors refocused on near-term growth challenges and operational changes including site actions and workforce reductions. Analysts set a median 6-month price target of $199, implying 27% upside from the current ~$155 price; the stock is 43% below its 52-week high.